Hermona Soreq: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
General update of scientific research since 2013
General update of scientific research since 2013
Line 27: Line 27:
Soreq started her scientific career in the Weizmann Institute, where she served as Senior Scientist and then Associate Professor (1979-1986). In 1986 she became an Associate Professor of Molecular Biology in the Department of Biological Chemistry at the Hebrew University of Jerusalem. In 1989 she gained her professorship there and set up her laboratory. She has run her lab there, ever-since. She served as the head of the [http://www.bio.huji.ac.il/eng/ Silberman Institute of Life Sciences at the Hebrew University] (1995-2000). In 2000 she was elected as President of the [http://www.tau.ac.il/lifesci/isbmb/ Israeli Society of Biochemistry and Molecular Biology], and served as such till 2002. In 2005 she was elected to serve a term of 3 years as the first female Dean of the Hebrew University's Faculty of Science.<ref>{{cite web|url=http://kavpnim.huji.ac.il/articles.asp?cat=15&artID=476|title=Appointment of Hermona Soreq as Dean of the Faculty of Mathematics & Sciences.|website=huji.ac.il|access-date=2013-04-23|archive-url=https://web.archive.org/web/20051215103740/http://kavpnim.huji.ac.il/articles.asp?cat=15&artID=476|archive-date=2005-12-15|url-status=dead}}</ref>
Soreq started her scientific career in the Weizmann Institute, where she served as Senior Scientist and then Associate Professor (1979-1986). In 1986 she became an Associate Professor of Molecular Biology in the Department of Biological Chemistry at the Hebrew University of Jerusalem. In 1989 she gained her professorship there and set up her laboratory. She has run her lab there, ever-since. She served as the head of the [http://www.bio.huji.ac.il/eng/ Silberman Institute of Life Sciences at the Hebrew University] (1995-2000). In 2000 she was elected as President of the [http://www.tau.ac.il/lifesci/isbmb/ Israeli Society of Biochemistry and Molecular Biology], and served as such till 2002. In 2005 she was elected to serve a term of 3 years as the first female Dean of the Hebrew University's Faculty of Science.<ref>{{cite web|url=http://kavpnim.huji.ac.il/articles.asp?cat=15&artID=476|title=Appointment of Hermona Soreq as Dean of the Faculty of Mathematics & Sciences.|website=huji.ac.il|access-date=2013-04-23|archive-url=https://web.archive.org/web/20051215103740/http://kavpnim.huji.ac.il/articles.asp?cat=15&artID=476|archive-date=2005-12-15|url-status=dead}}</ref>


Today, Soreq is The Charlotte Schlesinger Professor of Molecular Neuroscience at the Silberman Institute for Life Sciences and a founding member of the Hebrew University’s Edmond and Lily Safra Center for Brain Sciences, where she heads the Soreq group. Her major research interests are [[MicroRNA|MicroRNAs]] (miRs) and other non-coding RNA regulators of gene expression, including [[Transfer RNA|transfer RNA fragments]] (tRFs). Soreq combines advanced sequencing technologies with computational neuroscience and transgenic engineering tools to investigate miR and tRF functions in the healthy and diseased brain and body, with a focus on acetylcholine (ACh)-related processes. Her studies found primate-specific "CholinomiR" silencers of multiple genes that compete with each other on suppressing their targets and discovered cholinergic brain-to-body regulation of anxiety and inflammation.<ref>{{Cite journal|last=Soreq|first=Hermona|date=2015|title=Checks and balances on cholinergic signaling in brain and body function|url=https://pubmed.ncbi.nlm.nih.gov/26100140/|journal=Trends in Neurosciences|volume=38|issue=7|pages=448–458|doi=10.1016/j.tins.2015.05.007|issn=1878-108X|pmid=26100140}}</ref> In human volunteers, Soreq found cholinergic-associated pulse increases under fear of terror;<ref>{{Cite journal|last=Shenhar-Tsarfaty|first=Shani|last2=Yayon|first2=Nadav|last3=Waiskopf|first3=Nir|last4=Shapira|first4=Itzhak|last5=Toker|first5=Sharon|last6=Zaltser|first6=David|last7=Berliner|first7=Shlomo|last8=Ritov|first8=Ya'acov|last9=Soreq|first9=Hermona|date=2015|title=Fear and C-reactive protein cosynergize annual pulse increases in healthy adults|url=https://pubmed.ncbi.nlm.nih.gov/25535364/|journal=Proceedings of the National Academy of Sciences of the United States of America|volume=112|issue=5|pages=E467–471|doi=10.1073/pnas.1418264112|issn=1091-6490|pmc=4321278|pmid=25535364}}</ref> and identified massive CholinomiRs decline in Alzheimer’s brains,<ref>{{Cite journal|last=Barbash|first=Shahar|last2=Garfinkel|first2=Benjamin P.|last3=Maoz|first3=Rotem|last4=Simchovitz|first4=Alon|last5=Nadorp|first5=Bettina|last6=Guffanti|first6=Alessandro|last7=Bennett|first7=Estelle R.|last8=Nadeau|first8=Courtney|last9=Türk|first9=Andreas|last10=Paul|first10=Lukas|last11=Reda|first11=Torsten|date=2017|title=Alzheimer's brains show inter-related changes in RNA and lipid metabolism|url=https://pubmed.ncbi.nlm.nih.gov/28630030/|journal=Neurobiology of Disease|volume=106|pages=1–13|doi=10.1016/j.nbd.2017.06.008|issn=1095-953X|pmc=5560656|pmid=28630030}}</ref> which accompanies changes in long non-coding RNAs and points at Statins intervention with the onset of Parkinson’s disease<ref>{{Cite journal|last=Simchovitz|first=Alon|last2=Hanan|first2=Mor|last3=Yayon|first3=Nadav|last4=Lee|first4=Songhua|last5=Bennett|first5=Estelle R.|last6=Greenberg|first6=David S.|last7=Kadener|first7=Sebastian|last8=Soreq|first8=Hermona|date=2020|title=A lncRNA survey finds increases in neuroprotective LINC-PINT in Parkinson's disease substantia nigra|url=https://pubmed.ncbi.nlm.nih.gov/32080970/|journal=Aging Cell|volume=19|issue=3|pages=e13115|doi=10.1111/acel.13115|issn=1474-9726|pmc=7059180|pmid=32080970}}</ref> and modifications in pseudogenes expression.<ref>{{Cite journal|last=Barbash|first=S.|last2=Simchovitz|first2=A.|last3=Buchman|first3=A. S.|last4=Bennett|first4=D. A.|last5=Shifman|first5=S.|last6=Soreq|first6=H.|date=2017|title=Neuronal-expressed microRNA-targeted pseudogenes compete with coding genes in the human brain|url=https://pubmed.ncbi.nlm.nih.gov/28786976/|journal=Translational Psychiatry|volume=7|issue=8|pages=e1199|doi=10.1038/tp.2017.163|issn=2158-3188|pmc=5611730|pmid=28786976}}</ref> In engineered mice, Soreq studies CholinomiR and CholinotRF responders to stress, epilepsy,<ref>{{Cite journal|last=Bekenstein|first=Uriya|last2=Mishra|first2=Nibha|last3=Milikovsky|first3=Dan Z.|last4=Hanin|first4=Geula|last5=Zelig|first5=Daniel|last6=Sheintuch|first6=Liron|last7=Berson|first7=Amit|last8=Greenberg|first8=David S.|last9=Friedman|first9=Alon|last10=Soreq|first10=Hermona|date=2017|title=Dynamic changes in murine forebrain miR-211 expression associate with cholinergic imbalances and epileptiform activity|url=https://pubmed.ncbi.nlm.nih.gov/28584127/|journal=Proceedings of the National Academy of Sciences of the United States of America|volume=114|issue=25|pages=E4996–E5005|doi=10.1073/pnas.1701201114|issn=1091-6490|pmc=5488936|pmid=28584127}}</ref> inflammation<ref>{{Cite journal|last=Shaked|first=Iftach|last2=Meerson|first2=Ari|last3=Wolf|first3=Yochai|last4=Avni|first4=Ran|last5=Greenberg|first5=David|last6=Gilboa-Geffen|first6=Adi|last7=Soreq|first7=Hermona|date=2009|title=MicroRNA-132 potentiates cholinergic anti-inflammatory signaling by targeting acetylcholinesterase|url=https://pubmed.ncbi.nlm.nih.gov/20005135/|journal=Immunity|volume=31|issue=6|pages=965–973|doi=10.1016/j.immuni.2009.09.019|issn=1097-4180|pmid=20005135}}</ref> and ischemic stroke; and found liver fattening, trait anxiety, blood pressure and inflammation under inherited interference with acetylcholinesterase (AChE)-targeting CholinomiRs.<ref>{{Cite journal|last=Hanin|first=Geula|last2=Yayon|first2=Nadav|last3=Tzur|first3=Yonat|last4=Haviv|first4=Rotem|last5=Bennett|first5=Estelle R.|last6=Udi|first6=Shiran|last7=Krishnamoorthy|first7=Yoganathan R.|last8=Kotsiliti|first8=Eleni|last9=Zangen|first9=Rivka|last10=Efron|first10=Ben|last11=Tam|first11=Joseph|date=2018|title=miRNA-132 induces hepatic steatosis and hyperlipidaemia by synergistic multitarget suppression|url=https://pubmed.ncbi.nlm.nih.gov/28381526/|journal=Gut|volume=67|issue=6|pages=1124–1134|doi=10.1136/gutjnl-2016-312869|issn=1468-3288|pmc=5969364|pmid=28381526}}</ref> Soreq has found CholinomiR differences between brains of men and women with schizophrenia and bipolar disorder,<ref>{{Cite journal|last=Lobentanzer|first=Sebastian|last2=Hanin|first2=Geula|last3=Klein|first3=Jochen|last4=Soreq|first4=Hermona|date=2019|title=Integrative Transcriptomics Reveals Sexually Dimorphic Control of the Cholinergic/Neurokine Interface in Schizophrenia and Bipolar Disorder|url=https://pubmed.ncbi.nlm.nih.gov/31618642/|journal=Cell Reports|volume=29|issue=3|pages=764–777.e5|doi=10.1016/j.celrep.2019.09.017|issn=2211-1247|pmc=6899527|pmid=31618642}}</ref><ref>{{Cite journal|last=Simchovitz-Gesher|first=Alon|last2=Soreq|first2=Hermona|date=2020|title=Pharmaceutical Implications of Sex-Related RNA Divergence in Psychiatric Disorders|url=https://pubmed.ncbi.nlm.nih.gov/33012545/|journal=Trends in Pharmacological Sciences|volume=41|issue=11|pages=840–850|doi=10.1016/j.tips.2020.09.003|issn=1873-3735|pmid=33012545}}</ref> and CholinomiRs decline accompanied by CholinotRF increases in blood cells from stroke patients;<ref>{{Cite journal|last=Winek|first=Katarzyna|last2=Lobentanzer|first2=Sebastian|last3=Nadorp|first3=Bettina|last4=Dubnov|first4=Serafima|last5=Dames|first5=Claudia|last6=Jagdmann|first6=Sandra|last7=Moshitzky|first7=Gilli|last8=Hotter|first8=Benjamin|last9=Meisel|first9=Christian|last10=Greenberg|first10=David S.|last11=Shifman|first11=Sagiv|date=2020|title=Transfer RNA fragments replace microRNA regulators of the cholinergic poststroke immune blockade|url=https://pubmed.ncbi.nlm.nih.gov/33288717/|journal=Proceedings of the National Academy of Sciences of the United States of America|volume=117|issue=51|pages=32606–32616|doi=10.1073/pnas.2013542117|issn=1091-6490|pmc=7768686|pmid=33288717}}</ref> (Winek et al., 2020); together, her work leads to precision medicine-driven prevention and/or intervention with diseases involving impaired ACh signaling.
Today, Soreq is The Charlotte Schlesinger Professor of Molecular Neuroscience at the Silberman Institute for Life Sciences and a founding member of the Hebrew University’s Edmond and Lily Safra Center for Brain Sciences, where she heads the Soreq group. Her major research interests are [[MicroRNA|MicroRNAs]] (miRs) and other non-coding RNA regulators of gene expression, including [[Transfer RNA|transfer RNA fragments]] (tRFs). Soreq combines advanced sequencing technologies with computational neuroscience and transgenic engineering tools to investigate miR and tRF functions in the healthy and diseased brain and body, with a focus on acetylcholine (ACh)-related processes. Her studies found primate-specific "CholinomiR" silencers of multiple genes that compete with each other on suppressing their targets and discovered cholinergic brain-to-body regulation of anxiety and inflammation.<ref>{{Cite journal|last=Soreq|first=Hermona|date=2015|title=Checks and balances on cholinergic signaling in brain and body function|url=https://pubmed.ncbi.nlm.nih.gov/26100140/|journal=Trends in Neurosciences|volume=38|issue=7|pages=448–458|doi=10.1016/j.tins.2015.05.007|issn=1878-108X|pmid=26100140}}</ref> In human volunteers, Soreq found cholinergic-associated pulse increases under fear of terror;<ref name=":0">{{Cite journal|last=Shenhar-Tsarfaty|first=Shani|last2=Yayon|first2=Nadav|last3=Waiskopf|first3=Nir|last4=Shapira|first4=Itzhak|last5=Toker|first5=Sharon|last6=Zaltser|first6=David|last7=Berliner|first7=Shlomo|last8=Ritov|first8=Ya'acov|last9=Soreq|first9=Hermona|date=2015|title=Fear and C-reactive protein cosynergize annual pulse increases in healthy adults|url=https://pubmed.ncbi.nlm.nih.gov/25535364/|journal=Proceedings of the National Academy of Sciences of the United States of America|volume=112|issue=5|pages=E467–471|doi=10.1073/pnas.1418264112|issn=1091-6490|pmc=4321278|pmid=25535364}}</ref> and identified massive CholinomiRs decline in Alzheimer’s brains,<ref name=":1">{{Cite journal|last=Barbash|first=Shahar|last2=Garfinkel|first2=Benjamin P.|last3=Maoz|first3=Rotem|last4=Simchovitz|first4=Alon|last5=Nadorp|first5=Bettina|last6=Guffanti|first6=Alessandro|last7=Bennett|first7=Estelle R.|last8=Nadeau|first8=Courtney|last9=Türk|first9=Andreas|last10=Paul|first10=Lukas|last11=Reda|first11=Torsten|date=2017|title=Alzheimer's brains show inter-related changes in RNA and lipid metabolism|url=https://pubmed.ncbi.nlm.nih.gov/28630030/|journal=Neurobiology of Disease|volume=106|pages=1–13|doi=10.1016/j.nbd.2017.06.008|issn=1095-953X|pmc=5560656|pmid=28630030}}</ref> which accompanies changes in long non-coding RNAs and points at Statins intervention with the onset of Parkinson’s disease<ref>{{Cite journal|last=Simchovitz|first=Alon|last2=Hanan|first2=Mor|last3=Yayon|first3=Nadav|last4=Lee|first4=Songhua|last5=Bennett|first5=Estelle R.|last6=Greenberg|first6=David S.|last7=Kadener|first7=Sebastian|last8=Soreq|first8=Hermona|date=2020|title=A lncRNA survey finds increases in neuroprotective LINC-PINT in Parkinson's disease substantia nigra|url=https://pubmed.ncbi.nlm.nih.gov/32080970/|journal=Aging Cell|volume=19|issue=3|pages=e13115|doi=10.1111/acel.13115|issn=1474-9726|pmc=7059180|pmid=32080970}}</ref> and modifications in pseudogenes expression.<ref>{{Cite journal|last=Barbash|first=S.|last2=Simchovitz|first2=A.|last3=Buchman|first3=A. S.|last4=Bennett|first4=D. A.|last5=Shifman|first5=S.|last6=Soreq|first6=H.|date=2017|title=Neuronal-expressed microRNA-targeted pseudogenes compete with coding genes in the human brain|url=https://pubmed.ncbi.nlm.nih.gov/28786976/|journal=Translational Psychiatry|volume=7|issue=8|pages=e1199|doi=10.1038/tp.2017.163|issn=2158-3188|pmc=5611730|pmid=28786976}}</ref> In engineered mice, Soreq studies CholinomiR and CholinotRF responders to stress, epilepsy,<ref name=":2">{{Cite journal|last=Bekenstein|first=Uriya|last2=Mishra|first2=Nibha|last3=Milikovsky|first3=Dan Z.|last4=Hanin|first4=Geula|last5=Zelig|first5=Daniel|last6=Sheintuch|first6=Liron|last7=Berson|first7=Amit|last8=Greenberg|first8=David S.|last9=Friedman|first9=Alon|last10=Soreq|first10=Hermona|date=2017|title=Dynamic changes in murine forebrain miR-211 expression associate with cholinergic imbalances and epileptiform activity|url=https://pubmed.ncbi.nlm.nih.gov/28584127/|journal=Proceedings of the National Academy of Sciences of the United States of America|volume=114|issue=25|pages=E4996–E5005|doi=10.1073/pnas.1701201114|issn=1091-6490|pmc=5488936|pmid=28584127}}</ref> inflammation<ref name=":3">{{Cite journal|last=Shaked|first=Iftach|last2=Meerson|first2=Ari|last3=Wolf|first3=Yochai|last4=Avni|first4=Ran|last5=Greenberg|first5=David|last6=Gilboa-Geffen|first6=Adi|last7=Soreq|first7=Hermona|date=2009|title=MicroRNA-132 potentiates cholinergic anti-inflammatory signaling by targeting acetylcholinesterase|url=https://pubmed.ncbi.nlm.nih.gov/20005135/|journal=Immunity|volume=31|issue=6|pages=965–973|doi=10.1016/j.immuni.2009.09.019|issn=1097-4180|pmid=20005135}}</ref> and ischemic stroke; and found liver fattening, trait anxiety, blood pressure and inflammation under inherited interference with acetylcholinesterase (AChE)-targeting CholinomiRs.<ref name=":4">{{Cite journal|last=Hanin|first=Geula|last2=Yayon|first2=Nadav|last3=Tzur|first3=Yonat|last4=Haviv|first4=Rotem|last5=Bennett|first5=Estelle R.|last6=Udi|first6=Shiran|last7=Krishnamoorthy|first7=Yoganathan R.|last8=Kotsiliti|first8=Eleni|last9=Zangen|first9=Rivka|last10=Efron|first10=Ben|last11=Tam|first11=Joseph|date=2018|title=miRNA-132 induces hepatic steatosis and hyperlipidaemia by synergistic multitarget suppression|url=https://pubmed.ncbi.nlm.nih.gov/28381526/|journal=Gut|volume=67|issue=6|pages=1124–1134|doi=10.1136/gutjnl-2016-312869|issn=1468-3288|pmc=5969364|pmid=28381526}}</ref> Soreq has found CholinomiR differences between brains of men and women with schizophrenia and bipolar disorder,<ref name=":5">{{Cite journal|last=Lobentanzer|first=Sebastian|last2=Hanin|first2=Geula|last3=Klein|first3=Jochen|last4=Soreq|first4=Hermona|date=2019|title=Integrative Transcriptomics Reveals Sexually Dimorphic Control of the Cholinergic/Neurokine Interface in Schizophrenia and Bipolar Disorder|url=https://pubmed.ncbi.nlm.nih.gov/31618642/|journal=Cell Reports|volume=29|issue=3|pages=764–777.e5|doi=10.1016/j.celrep.2019.09.017|issn=2211-1247|pmc=6899527|pmid=31618642}}</ref><ref>{{Cite journal|last=Simchovitz-Gesher|first=Alon|last2=Soreq|first2=Hermona|date=2020|title=Pharmaceutical Implications of Sex-Related RNA Divergence in Psychiatric Disorders|url=https://pubmed.ncbi.nlm.nih.gov/33012545/|journal=Trends in Pharmacological Sciences|volume=41|issue=11|pages=840–850|doi=10.1016/j.tips.2020.09.003|issn=1873-3735|pmid=33012545}}</ref> and CholinomiRs decline accompanied by CholinotRF increases in blood cells from stroke patients;<ref name=":6">{{Cite journal|last=Winek|first=Katarzyna|last2=Lobentanzer|first2=Sebastian|last3=Nadorp|first3=Bettina|last4=Dubnov|first4=Serafima|last5=Dames|first5=Claudia|last6=Jagdmann|first6=Sandra|last7=Moshitzky|first7=Gilli|last8=Hotter|first8=Benjamin|last9=Meisel|first9=Christian|last10=Greenberg|first10=David S.|last11=Shifman|first11=Sagiv|date=2020|title=Transfer RNA fragments replace microRNA regulators of the cholinergic poststroke immune blockade|url=https://pubmed.ncbi.nlm.nih.gov/33288717/|journal=Proceedings of the National Academy of Sciences of the United States of America|volume=117|issue=51|pages=32606–32616|doi=10.1073/pnas.2013542117|issn=1091-6490|pmc=7768686|pmid=33288717}}</ref> (Winek et al., 2020); together, her work leads to precision medicine-driven prevention and/or intervention with diseases involving impaired ACh signaling.

=== Major landmarks of the Soreq group in the cholinergic field ===

* MiR-132 regulation of cholinergic signaling: Soreq found miR-132 suppression of AChE levels and activities, controlling neuro-immune signaling from brain to body,<ref name=":3" /> with a pronounced impact on liver hyperlipidemia.<ref name=":4" />
* CholinomiRs-mediated suppression of stress reactions: miR-211 was identified as attenuator of epileptic seizures<ref name=":2" /> and its sequence homologue miR-204 was associated with stereotypic behavior;<ref>{{Cite journal|last=Moshitzky|first=Gilli|last2=Shoham|first2=Shai|last3=Madrer|first3=Nimrod|last4=Husain|first4=Amir Mouhammed|last5=Greenberg|first5=David S.|last6=Yirmiya|first6=Raz|last7=Ben-Shaul|first7=Yoram|last8=Soreq|first8=Hermona|date=2020|title=Cholinergic Stress Signals Accompany MicroRNA-Associated Stereotypic Behavior and Glutamatergic Neuromodulation in the Prefrontal Cortex|url=https://pubmed.ncbi.nlm.nih.gov/32503154/|journal=Biomolecules|volume=10|issue=6|doi=10.3390/biom10060848|issn=2218-273X|pmc=7355890|pmid=32503154}}</ref> human carriers of a single nucleotide polymorphism (SNP) that modifies miR-608-binding site in AChE mRNA showed elevated brain AChE, blood pressure and inflammation but not PTSD;<ref>{{Cite journal|last=Hanin|first=Geula|last2=Shenhar-Tsarfaty|first2=Shani|last3=Yayon|first3=Nadav|last4=Yau|first4=Yin Hoe|last5=Hoe|first5=Yau Yin|last6=Bennett|first6=Estelle R.|last7=Sklan|first7=Ella H.|last8=Rao|first8=Dabeeru C.|last9=Rankinen|first9=Tuomo|last10=Bouchard|first10=Claude|last11=Geifman-Shochat|first11=Susana|date=2014|title=Competing targets of microRNA-608 affect anxiety and hypertension|url=https://pubmed.ncbi.nlm.nih.gov/24722204/|journal=Human Molecular Genetics|volume=23|issue=17|pages=4569–4580|doi=10.1093/hmg/ddu170|issn=1460-2083|pmc=4119407|pmid=24722204}}</ref><ref>{{Cite journal|last=Lin|first=T.|last2=Simchovitz|first2=A.|last3=Shenhar-Tsarfaty|first3=S.|last4=Vaisvaser|first4=S.|last5=Admon|first5=R.|last6=Hanin|first6=G.|last7=Hanan|first7=M.|last8=Kliper|first8=E.|last9=Bar-Haim|first9=Y.|last10=Shomron|first10=N.|last11=Fernandez|first11=G.|date=2016|title=Intensified vmPFC surveillance over PTSS under perturbed microRNA-608/AChE interaction|url=https://pubmed.ncbi.nlm.nih.gov/27138800/|journal=Translational Psychiatry|volume=6|pages=e801|doi=10.1038/tp.2016.70|issn=2158-3188|pmc=5070052|pmid=27138800}}</ref> whereas the AChE-targeting miR-125b was shown to be schizophrenia-modulated.<ref name=":5" />
* CholinomiRs-associated changes in stroke, cardiac and inflammatory bowel disease: Together with clinician collaborators, Soreq observed serum AChE changes that predict recovery and survival from ischemic stroke;<ref>{{Cite journal|last=Ben Assayag|first=Einor|last2=Shenhar-Tsarfaty|first2=Shani|last3=Ofek|first3=Keren|last4=Soreq|first4=Lilach|last5=Bova|first5=Irena|last6=Shopin|first6=Ludmila|last7=Berg|first7=Ronan M. G.|last8=Berliner|first8=Shlomo|last9=Shapira|first9=Itzhak|last10=Bornstein|first10=Natan M.|last11=Soreq|first11=Hermona|date=2010|title=Serum cholinesterase activities distinguish between stroke patients and controls and predict 12-month mortality|url=https://pubmed.ncbi.nlm.nih.gov/20464061/|journal=Molecular Medicine (Cambridge, Mass.)|volume=16|issue=7-8|pages=278–286|doi=10.2119/molmed.2010.00015|issn=1528-3658|pmc=2896466|pmid=20464061}}</ref> drastic miR-132 increases in inflamed, but not non-inflamed intestinal biopsies,<ref>{{Cite journal|last=Maharshak|first=Nitsan|last2=Shenhar-Tsarfaty|first2=Shani|last3=Aroyo|first3=Nimrod|last4=Orpaz|first4=Naama|last5=Guberman|first5=Irene|last6=Canaani|first6=Jonathan|last7=Halpern|first7=Zamir|last8=Dotan|first8=Iris|last9=Berliner|first9=Shlomo|last10=Soreq|first10=Hermona|date=2013|title=MicroRNA-132 modulates cholinergic signaling and inflammation in human inflammatory bowel disease|url=https://pubmed.ncbi.nlm.nih.gov/23598815/|journal=Inflammatory Bowel Diseases|volume=19|issue=7|pages=1346–1353|doi=10.1097/MIB.0b013e318281f47d|issn=1536-4844|pmid=23598815}}</ref> and risk of non-survival in cardiac patients with low AChE levels.<ref>{{Cite journal|last=Arbel|first=Yaron|last2=Shenhar-Tsarfaty|first2=Shani|last3=Waiskopf|first3=Nir|last4=Finkelstein|first4=Ariel|last5=Halkin|first5=Amir|last6=Revivo|first6=Miri|last7=Berliner|first7=Shlomo|last8=Herz|first8=Itzhak|last9=Shapira|first9=Itzhak|last10=Keren|first10=Gad|last11=Soreq|first11=Hermona|date=2014|title=Decline in serum cholinesterase activities predicts 2-year major adverse cardiac events|url=https://pubmed.ncbi.nlm.nih.gov/24395570/|journal=Molecular Medicine (Cambridge, Mass.)|volume=20|pages=38–45|doi=10.2119/molmed.2013.00139|issn=1528-3658|pmc=3951463|pmid=24395570}}</ref> Surprisingly, in stroke patients’ blood cholinomiRs are exchanged with cholino-targeted transfer RNA fragments.<ref name=":6" />
* Finding cholinergic-mediated RNA metabolism impairments in neurodegenerating brains: Soreq found the decline in Alzheimer’s cholinergic neurons and Parkinson’s disease brains to be accompanied by RNA metabolism-related brain damages in human donors and cholinergic-deprived mice.<ref>{{Cite journal|last=Berson|first=Amit|last2=Barbash|first2=Shahar|last3=Shaltiel|first3=Galit|last4=Goll|first4=Yael|last5=Hanin|first5=Geula|last6=Greenberg|first6=David S.|last7=Ketzef|first7=Maya|last8=Becker|first8=Albert J.|last9=Friedman|first9=Alon|last10=Soreq|first10=Hermona|date=2012|title=Cholinergic-associated loss of hnRNP-A/B in Alzheimer's disease impairs cortical splicing and cognitive function in mice|url=https://pubmed.ncbi.nlm.nih.gov/22628224/|journal=EMBO molecular medicine|volume=4|issue=8|pages=730–742|doi=10.1002/emmm.201100995|issn=1757-4684|pmc=3494073|pmid=22628224}}</ref><ref name=":1" /><ref>{{Cite journal|last=Hanan|first=Mor|last2=Simchovitz|first2=Alon|last3=Yayon|first3=Nadav|last4=Vaknine|first4=Shani|last5=Cohen-Fultheim|first5=Roni|last6=Karmon|first6=Miriam|last7=Madrer|first7=Nimrod|last8=Rohrlich|first8=Talia Miriam|last9=Maman|first9=Moria|last10=Bennett|first10=Estelle R.|last11=Greenberg|first11=David S.|date=2020|title=A Parkinson's disease CircRNAs Resource reveals a link between circSLC8A1 and oxidative stress|url=https://pubmed.ncbi.nlm.nih.gov/32715657/|journal=EMBO molecular medicine|volume=12|issue=9|pages=e11942|doi=10.15252/emmm.201911942|issn=1757-4684|pmc=7507321|pmid=32715657}}</ref>
* Implicating cholinergic mechanisms to our stress-related daily life: The impact of stress-induced processes on our daily life in 2021 Israel is notably increasing the risk of disease; in a collaborative Big-Data study with clinical experts, Soreq and colleagues combined machine learning with patient serum tests<ref name=":0" /> which linked anxiety and metabolism regulating miRs.<ref>{{Cite journal|last=Meydan|first=Chanan|last2=Shenhar-Tsarfaty|first2=Shani|last3=Soreq|first3=Hermona|date=2016|title=MicroRNA Regulators of Anxiety and Metabolic Disorders|url=https://pubmed.ncbi.nlm.nih.gov/27496210/|journal=Trends in Molecular Medicine|volume=22|issue=9|pages=798–812|doi=10.1016/j.molmed.2016.07.001|issn=1471-499X|pmid=27496210}}</ref> Soreq thus raised research discussion of cholinergic-regulating small RNAs at both the basic and biomedical aspects.


She is the author of over 280 peer-reviewed journal articles and 8 books
She is the author of over 280 peer-reviewed journal articles and 8 books
Line 41: Line 49:
*2013 National Center of Excellence (I-Core) on Trauma,<ref>{{cite web|url=http://www.i-core.org.il/mass-trauma-research-|title=Mass Trauma Research|website=www.i-core.org.il}}</ref> member of Scientific Management
*2013 National Center of Excellence (I-Core) on Trauma,<ref>{{cite web|url=http://www.i-core.org.il/mass-trauma-research-|title=Mass Trauma Research|website=www.i-core.org.il}}</ref> member of Scientific Management
*2013 Advanced ERC Research Award
*2013 Advanced ERC Research Award
*2015 The Rappaport Prize for Bio-Medical Research, Israel<ref>{{Cite web|title=Rappaport prize 2015|url=https://www.rappaport-prize.org.il/en/hermona-soreq|url-status=live|website=rappaport-prize.org.il}}</ref>
*2017 ILANIT-Katzir Prize for exceptional achievements in the Life Sciences, Israel<ref>{{Cite web|title=ILANIT-Katzir prize 2017|url=https://www.fiseb.org/ilanit-2020/ilanit-katzir-prize-2020/|url-status=live|website=www.fiseb.org}}</ref>
She has also received honorary Doctorates from the [[University of Erlangen]], Nűremberg, Germany (2007), [[Ben-Gurion University of the Negev]], Israel (2007) and the [[University of Stockholm]], Sweden, (1996)
She has also received honorary Doctorates from the [[University of Erlangen]], Nűremberg, Germany (2007), [[Ben-Gurion University of the Negev]], Israel (2007) and the [[University of Stockholm]], Sweden, (1996)


Revision as of 11:00, 5 May 2021

Hermona Soreq
Prof. Hermona Soreq, November 2013
Born
Hermona Even

(1947-04-03) April 3, 1947 (age 77)
Tel Aviv, Israel
NationalityIsraeli
Alma materTel-Aviv University
The Hebrew University of Jerusalem
Weizmann Institute of Science
Known forResearch in microRNAs (miRs) and other non-coding RNA regulators of gene expression focusing on acetylcholine(ACh)-related processes
Scientific career
FieldsMolecular Neuroscience
InstitutionsThe Hebrew University of Jerusalem

Hermona Soreq (חרמונה שורק) is an Israeli professor of Molecular Neuroscience at The Hebrew University of Jerusalem.[1] Best known for her work on the signaling of acetylcholine and its relevance in stress responses and neurodegenerative diseases such as Parkinson's and Alzheimer's.

Biography

Soreq (née Even) was born in Tel-Aviv. She completed her B.Sc. in Biochemistry and Microbiology at the Hebrew University, M.Sc. in Biochemistry from Tel-Aviv University and Ph.D. in Biochemistry from the Weizmann Institute in 1976. From 1977 to 1979, she was a post-doctoral Fogarty fellow, in Molecular Cell Biology, at the Rockefeller University, New York.

Scientific career

Soreq started her scientific career in the Weizmann Institute, where she served as Senior Scientist and then Associate Professor (1979-1986). In 1986 she became an Associate Professor of Molecular Biology in the Department of Biological Chemistry at the Hebrew University of Jerusalem. In 1989 she gained her professorship there and set up her laboratory. She has run her lab there, ever-since. She served as the head of the Silberman Institute of Life Sciences at the Hebrew University (1995-2000). In 2000 she was elected as President of the Israeli Society of Biochemistry and Molecular Biology, and served as such till 2002. In 2005 she was elected to serve a term of 3 years as the first female Dean of the Hebrew University's Faculty of Science.[2]

Today, Soreq is The Charlotte Schlesinger Professor of Molecular Neuroscience at the Silberman Institute for Life Sciences and a founding member of the Hebrew University’s Edmond and Lily Safra Center for Brain Sciences, where she heads the Soreq group. Her major research interests are MicroRNAs (miRs) and other non-coding RNA regulators of gene expression, including transfer RNA fragments (tRFs). Soreq combines advanced sequencing technologies with computational neuroscience and transgenic engineering tools to investigate miR and tRF functions in the healthy and diseased brain and body, with a focus on acetylcholine (ACh)-related processes. Her studies found primate-specific "CholinomiR" silencers of multiple genes that compete with each other on suppressing their targets and discovered cholinergic brain-to-body regulation of anxiety and inflammation.[3] In human volunteers, Soreq found cholinergic-associated pulse increases under fear of terror;[4] and identified massive CholinomiRs decline in Alzheimer’s brains,[5] which accompanies changes in long non-coding RNAs and points at Statins intervention with the onset of Parkinson’s disease[6] and modifications in pseudogenes expression.[7] In engineered mice, Soreq studies CholinomiR and CholinotRF responders to stress, epilepsy,[8] inflammation[9] and ischemic stroke; and found liver fattening, trait anxiety, blood pressure and inflammation under inherited interference with acetylcholinesterase (AChE)-targeting CholinomiRs.[10] Soreq has found CholinomiR differences between brains of men and women with schizophrenia and bipolar disorder,[11][12] and CholinomiRs decline accompanied by CholinotRF increases in blood cells from stroke patients;[13] (Winek et al., 2020); together, her work leads to precision medicine-driven prevention and/or intervention with diseases involving impaired ACh signaling.

Major landmarks of the Soreq group in the cholinergic field

  • MiR-132 regulation of cholinergic signaling: Soreq found miR-132 suppression of AChE levels and activities, controlling neuro-immune signaling from brain to body,[9] with a pronounced impact on liver hyperlipidemia.[10]
  • CholinomiRs-mediated suppression of stress reactions: miR-211 was identified as attenuator of epileptic seizures[8] and its sequence homologue miR-204 was associated with stereotypic behavior;[14] human carriers of a single nucleotide polymorphism (SNP) that modifies miR-608-binding site in AChE mRNA showed elevated brain AChE, blood pressure and inflammation but not PTSD;[15][16] whereas the AChE-targeting miR-125b was shown to be schizophrenia-modulated.[11]
  • CholinomiRs-associated changes in stroke, cardiac and inflammatory bowel disease: Together with clinician collaborators, Soreq observed serum AChE changes that predict recovery and survival from ischemic stroke;[17] drastic miR-132 increases in inflamed, but not non-inflamed intestinal biopsies,[18] and risk of non-survival in cardiac patients with low AChE levels.[19] Surprisingly, in stroke patients’ blood cholinomiRs are exchanged with cholino-targeted transfer RNA fragments.[13]
  • Finding cholinergic-mediated RNA metabolism impairments in neurodegenerating brains: Soreq found the decline in Alzheimer’s cholinergic neurons and Parkinson’s disease brains to be accompanied by RNA metabolism-related brain damages in human donors and cholinergic-deprived mice.[20][5][21]
  • Implicating cholinergic mechanisms to our stress-related daily life: The impact of stress-induced processes on our daily life in 2021 Israel is notably increasing the risk of disease; in a collaborative Big-Data study with clinical experts, Soreq and colleagues combined machine learning with patient serum tests[4] which linked anxiety and metabolism regulating miRs.[22] Soreq thus raised research discussion of cholinergic-regulating small RNAs at both the basic and biomedical aspects.

She is the author of over 280 peer-reviewed journal articles and 8 books

Awards and honors

Soreq serves on the boards of the Hebrew University, the Technion (Israel Institute of Technology) and Yissum (the Research Development Company of the Hebrew University). She is also an Adjunct Research professor at the Arizona State University Biodesign Institute. Her awards and honors include:

  • 2005 Landau Prize for Biomedical Research
  • 2008 Kaye Prize for Innovative research, The Hebrew University[23]
  • 2009 The Lise Meitner Alexander von Humboldt Foundation Award, Germany
  • 2009 Visiting Miller Professorship,[24] University of California, Berkeley
  • 2013 National Center of Excellence (I-Core) on Trauma,[25] member of Scientific Management
  • 2013 Advanced ERC Research Award
  • 2015 The Rappaport Prize for Bio-Medical Research, Israel[26]
  • 2017 ILANIT-Katzir Prize for exceptional achievements in the Life Sciences, Israel[27]

She has also received honorary Doctorates from the University of Erlangen, Nűremberg, Germany (2007), Ben-Gurion University of the Negev, Israel (2007) and the University of Stockholm, Sweden, (1996)

Publications

  • Loewenstein-Lichtenstein, Yael; Schwarz, Mikael; Glick, David; Nørgaard-Pedersen, Bent; Zakut, Haim; Soreq, Hermona (1995). "Genetic predisposition to adverse consequences of anti–cholinesterases in 'atypical' BCHE carriers". Nature Medicine. 1 (10): 1082–5. doi:10.1038/nm1095-1082. PMID 7489367. S2CID 1906128.
  • Friedman, Alon; Kaufer, Daniela; Shemer, Joshua; Hendler, Israel; Soreq, Hermona; Tur-Kaspa, Ilan (1996). "Pyridostigmine brain penetration under stress enhances neuronal excitability and induces early immediate transcriptional response". Nature Medicine. 2 (12): 1382–5. doi:10.1038/nm1296-1382. PMID 8946841. S2CID 7955488.
  • Kaufer, Daniela; Friedman, Alon; Seidman, Shlomo; Soreq, Hermona (1998). "Acute stress facilitates long-lasting changes in cholinergic gene expression". Nature. 393 (6683): 373–7. Bibcode:1998Natur.393..373K. doi:10.1038/30741. PMID 9620801. S2CID 4409716. Accompanied by: Sapolsky, Robert M. (1998). "The stress of Gulf War syndrome". Nature. 393 (6683): 308–9. doi:10.1038/30606. PMID 9620793.
  • Meshorer, Eran; Erb, Christina; Gazit, Roi; Pavlovsky, Lev; Kaufer, Daniela; Friedman, Alon; Glick, David; Ben-Arie, Nissim; Soreq, Hermona (2002). "Alternative Splicing and Neuritic mRNA Translocation Under Long-Term Neuronal Hypersensitivity". Science. 295 (5554): 508–12. Bibcode:2002Sci...295..508M. doi:10.1126/science.1066752. PMID 11799248. S2CID 8773254.
  • Shaked, Iftach; Meerson, Ari; Wolf, Yochai; Avni, Ran; Greenberg, David; Gilboa-Geffen, Adi; Soreq, Hermona (2009). "MicroRNA-132 Potentiates Cholinergic Anti-Inflammatory Signaling by Targeting Acetylcholinesterase". Immunity. 31 (6): 965–73. doi:10.1016/j.immuni.2009.09.019. PMID 20005135.
  • Berson, Amit; Barbash, Shahar; Shaltiel, Galit; Goll, Yael; Hanin, Geula; Greenberg, David S.; Ketzef, Maya; Becker, Albert J; Friedman, Alon; Soreq, Hermona (2012). "Cholinergic-associated loss of hnRNP-A/B in Alzheimer's disease impairs cortical splicing and cognitive function in mice". EMBO Molecular Medicine. 4 (8): 730–42. doi:10.1002/emmm.201100995. PMC 3494073. PMID 22628224.

References

  1. ^ Hermona Soreq at the Edmond & Lily Safra Center for Brain Sciences, the Hebrew University of Jerusalem
  2. ^ "Appointment of Hermona Soreq as Dean of the Faculty of Mathematics & Sciences". huji.ac.il. Archived from the original on 2005-12-15. Retrieved 2013-04-23.
  3. ^ Soreq, Hermona (2015). "Checks and balances on cholinergic signaling in brain and body function". Trends in Neurosciences. 38 (7): 448–458. doi:10.1016/j.tins.2015.05.007. ISSN 1878-108X. PMID 26100140.
  4. ^ a b Shenhar-Tsarfaty, Shani; Yayon, Nadav; Waiskopf, Nir; Shapira, Itzhak; Toker, Sharon; Zaltser, David; Berliner, Shlomo; Ritov, Ya'acov; Soreq, Hermona (2015). "Fear and C-reactive protein cosynergize annual pulse increases in healthy adults". Proceedings of the National Academy of Sciences of the United States of America. 112 (5): E467–471. doi:10.1073/pnas.1418264112. ISSN 1091-6490. PMC 4321278. PMID 25535364.
  5. ^ a b Barbash, Shahar; Garfinkel, Benjamin P.; Maoz, Rotem; Simchovitz, Alon; Nadorp, Bettina; Guffanti, Alessandro; Bennett, Estelle R.; Nadeau, Courtney; Türk, Andreas; Paul, Lukas; Reda, Torsten (2017). "Alzheimer's brains show inter-related changes in RNA and lipid metabolism". Neurobiology of Disease. 106: 1–13. doi:10.1016/j.nbd.2017.06.008. ISSN 1095-953X. PMC 5560656. PMID 28630030.
  6. ^ Simchovitz, Alon; Hanan, Mor; Yayon, Nadav; Lee, Songhua; Bennett, Estelle R.; Greenberg, David S.; Kadener, Sebastian; Soreq, Hermona (2020). "A lncRNA survey finds increases in neuroprotective LINC-PINT in Parkinson's disease substantia nigra". Aging Cell. 19 (3): e13115. doi:10.1111/acel.13115. ISSN 1474-9726. PMC 7059180. PMID 32080970.
  7. ^ Barbash, S.; Simchovitz, A.; Buchman, A. S.; Bennett, D. A.; Shifman, S.; Soreq, H. (2017). "Neuronal-expressed microRNA-targeted pseudogenes compete with coding genes in the human brain". Translational Psychiatry. 7 (8): e1199. doi:10.1038/tp.2017.163. ISSN 2158-3188. PMC 5611730. PMID 28786976.
  8. ^ a b Bekenstein, Uriya; Mishra, Nibha; Milikovsky, Dan Z.; Hanin, Geula; Zelig, Daniel; Sheintuch, Liron; Berson, Amit; Greenberg, David S.; Friedman, Alon; Soreq, Hermona (2017). "Dynamic changes in murine forebrain miR-211 expression associate with cholinergic imbalances and epileptiform activity". Proceedings of the National Academy of Sciences of the United States of America. 114 (25): E4996–E5005. doi:10.1073/pnas.1701201114. ISSN 1091-6490. PMC 5488936. PMID 28584127.
  9. ^ a b Shaked, Iftach; Meerson, Ari; Wolf, Yochai; Avni, Ran; Greenberg, David; Gilboa-Geffen, Adi; Soreq, Hermona (2009). "MicroRNA-132 potentiates cholinergic anti-inflammatory signaling by targeting acetylcholinesterase". Immunity. 31 (6): 965–973. doi:10.1016/j.immuni.2009.09.019. ISSN 1097-4180. PMID 20005135.
  10. ^ a b Hanin, Geula; Yayon, Nadav; Tzur, Yonat; Haviv, Rotem; Bennett, Estelle R.; Udi, Shiran; Krishnamoorthy, Yoganathan R.; Kotsiliti, Eleni; Zangen, Rivka; Efron, Ben; Tam, Joseph (2018). "miRNA-132 induces hepatic steatosis and hyperlipidaemia by synergistic multitarget suppression". Gut. 67 (6): 1124–1134. doi:10.1136/gutjnl-2016-312869. ISSN 1468-3288. PMC 5969364. PMID 28381526.
  11. ^ a b Lobentanzer, Sebastian; Hanin, Geula; Klein, Jochen; Soreq, Hermona (2019). "Integrative Transcriptomics Reveals Sexually Dimorphic Control of the Cholinergic/Neurokine Interface in Schizophrenia and Bipolar Disorder". Cell Reports. 29 (3): 764–777.e5. doi:10.1016/j.celrep.2019.09.017. ISSN 2211-1247. PMC 6899527. PMID 31618642.
  12. ^ Simchovitz-Gesher, Alon; Soreq, Hermona (2020). "Pharmaceutical Implications of Sex-Related RNA Divergence in Psychiatric Disorders". Trends in Pharmacological Sciences. 41 (11): 840–850. doi:10.1016/j.tips.2020.09.003. ISSN 1873-3735. PMID 33012545.
  13. ^ a b Winek, Katarzyna; Lobentanzer, Sebastian; Nadorp, Bettina; Dubnov, Serafima; Dames, Claudia; Jagdmann, Sandra; Moshitzky, Gilli; Hotter, Benjamin; Meisel, Christian; Greenberg, David S.; Shifman, Sagiv (2020). "Transfer RNA fragments replace microRNA regulators of the cholinergic poststroke immune blockade". Proceedings of the National Academy of Sciences of the United States of America. 117 (51): 32606–32616. doi:10.1073/pnas.2013542117. ISSN 1091-6490. PMC 7768686. PMID 33288717.
  14. ^ Moshitzky, Gilli; Shoham, Shai; Madrer, Nimrod; Husain, Amir Mouhammed; Greenberg, David S.; Yirmiya, Raz; Ben-Shaul, Yoram; Soreq, Hermona (2020). "Cholinergic Stress Signals Accompany MicroRNA-Associated Stereotypic Behavior and Glutamatergic Neuromodulation in the Prefrontal Cortex". Biomolecules. 10 (6). doi:10.3390/biom10060848. ISSN 2218-273X. PMC 7355890. PMID 32503154.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  15. ^ Hanin, Geula; Shenhar-Tsarfaty, Shani; Yayon, Nadav; Yau, Yin Hoe; Hoe, Yau Yin; Bennett, Estelle R.; Sklan, Ella H.; Rao, Dabeeru C.; Rankinen, Tuomo; Bouchard, Claude; Geifman-Shochat, Susana (2014). "Competing targets of microRNA-608 affect anxiety and hypertension". Human Molecular Genetics. 23 (17): 4569–4580. doi:10.1093/hmg/ddu170. ISSN 1460-2083. PMC 4119407. PMID 24722204.
  16. ^ Lin, T.; Simchovitz, A.; Shenhar-Tsarfaty, S.; Vaisvaser, S.; Admon, R.; Hanin, G.; Hanan, M.; Kliper, E.; Bar-Haim, Y.; Shomron, N.; Fernandez, G. (2016). "Intensified vmPFC surveillance over PTSS under perturbed microRNA-608/AChE interaction". Translational Psychiatry. 6: e801. doi:10.1038/tp.2016.70. ISSN 2158-3188. PMC 5070052. PMID 27138800.
  17. ^ Ben Assayag, Einor; Shenhar-Tsarfaty, Shani; Ofek, Keren; Soreq, Lilach; Bova, Irena; Shopin, Ludmila; Berg, Ronan M. G.; Berliner, Shlomo; Shapira, Itzhak; Bornstein, Natan M.; Soreq, Hermona (2010). "Serum cholinesterase activities distinguish between stroke patients and controls and predict 12-month mortality". Molecular Medicine (Cambridge, Mass.). 16 (7–8): 278–286. doi:10.2119/molmed.2010.00015. ISSN 1528-3658. PMC 2896466. PMID 20464061.
  18. ^ Maharshak, Nitsan; Shenhar-Tsarfaty, Shani; Aroyo, Nimrod; Orpaz, Naama; Guberman, Irene; Canaani, Jonathan; Halpern, Zamir; Dotan, Iris; Berliner, Shlomo; Soreq, Hermona (2013). "MicroRNA-132 modulates cholinergic signaling and inflammation in human inflammatory bowel disease". Inflammatory Bowel Diseases. 19 (7): 1346–1353. doi:10.1097/MIB.0b013e318281f47d. ISSN 1536-4844. PMID 23598815.
  19. ^ Arbel, Yaron; Shenhar-Tsarfaty, Shani; Waiskopf, Nir; Finkelstein, Ariel; Halkin, Amir; Revivo, Miri; Berliner, Shlomo; Herz, Itzhak; Shapira, Itzhak; Keren, Gad; Soreq, Hermona (2014). "Decline in serum cholinesterase activities predicts 2-year major adverse cardiac events". Molecular Medicine (Cambridge, Mass.). 20: 38–45. doi:10.2119/molmed.2013.00139. ISSN 1528-3658. PMC 3951463. PMID 24395570.
  20. ^ Berson, Amit; Barbash, Shahar; Shaltiel, Galit; Goll, Yael; Hanin, Geula; Greenberg, David S.; Ketzef, Maya; Becker, Albert J.; Friedman, Alon; Soreq, Hermona (2012). "Cholinergic-associated loss of hnRNP-A/B in Alzheimer's disease impairs cortical splicing and cognitive function in mice". EMBO molecular medicine. 4 (8): 730–742. doi:10.1002/emmm.201100995. ISSN 1757-4684. PMC 3494073. PMID 22628224.
  21. ^ Hanan, Mor; Simchovitz, Alon; Yayon, Nadav; Vaknine, Shani; Cohen-Fultheim, Roni; Karmon, Miriam; Madrer, Nimrod; Rohrlich, Talia Miriam; Maman, Moria; Bennett, Estelle R.; Greenberg, David S. (2020). "A Parkinson's disease CircRNAs Resource reveals a link between circSLC8A1 and oxidative stress". EMBO molecular medicine. 12 (9): e11942. doi:10.15252/emmm.201911942. ISSN 1757-4684. PMC 7507321. PMID 32715657.
  22. ^ Meydan, Chanan; Shenhar-Tsarfaty, Shani; Soreq, Hermona (2016). "MicroRNA Regulators of Anxiety and Metabolic Disorders". Trends in Molecular Medicine. 22 (9): 798–812. doi:10.1016/j.molmed.2016.07.001. ISSN 1471-499X. PMID 27496210.
  23. ^ "Kaye Prize recipients, 2008" (PDF). huji.ac.il.
  24. ^ List of visiting Miller Professors Archived 2012-07-24 at the Wayback Machine
  25. ^ "Mass Trauma Research". www.i-core.org.il.
  26. ^ "Rappaport prize 2015". rappaport-prize.org.il.{{cite web}}: CS1 maint: url-status (link)
  27. ^ "ILANIT-Katzir prize 2017". www.fiseb.org.{{cite web}}: CS1 maint: url-status (link)

External links

Wikimedia Commons has media related to Hermona Soreq.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Hermona_Soreq&oldid=1021556831"